Program

November 4-8, 2019. Lima, Peru




Confirmed speakers


Bo Lönnerdal, PhD
University of California, Davis, USA
“Biological activities of the human milk lactoferrin-osteopontin complex”

Hans Vogel, PhD
University of Calgary, Canada
“Antibiofilm and anticancer activities of lactoferrin-derived antimicrobial peptides”

Nidia Leon-Sicarios, PhD
Universidad Autónoma de Sinaloa, México
“Lactoferrin and lactoferrin peptides against multi-drug resistant bacteria”

Jianhua Wang, PhD
Feed Research Institute, China
“Molecular modification and characteristics of lactericcin deriavates of anti-trypsin proteolysis”

Anthony Schryvers, PhD
University of Calgary, Canada
“Bacterial lactoferrin receptors – An Evolutionary Perspective”

Vadim Vasilyev, PhD
Institute of Experimental Medicine, Saint-Petersburg, Russia
“Lactoferrin rescues cognitive functions in the offspring of rats subjected to hypoxia in pregnancy”

Jeffrey Actor, PhD
University of Texas - Houston, USA
“Lactoferrin Treatment Alters Macrophage Phenotypes to Permit Drug Penetration to Mycobacterial Granulomas”

Marian Kruzel, PhD
UT Health McGovern Medical School at Houston, USA
“Systemic effects of dietary lactoferrin: bioequivalence of human versus bovine lactoferrin”

Sebastian Peter Galuska, PhD
Leibniz Institute for Farm Animal Biology (FBN), Germany
"Lactoferrin interacts with polysialic acid: MacGyver gets a dynamic tool"

Antimo Cutone, PhD
University of Molise, Italy
"Native and iron-saturated bovine lactoferrin differently hinder migration in a model of human glioblastoma by reverting epithelial-to-mesenchymal transition-like process and inhibiting interleukin-6/STAT3 axis"

María Stefania Lepanto, Msc
University La Sapienza of Rome, Italy
"Effect of bovine lactoferrin on invasion and intracellular survival of adherent-invasive Escherichia coli LF82 as well as on bacteria-induced DNA damage in differentiated human enterocytes"

Staffan Berglund, PhD
Umeå University, Sweden
"The LIME study: Clinical effects of bovine lactoferrin and lower iron content in infant formula"

Eric Brian Nonnecke, PhD
University of California, Davis, USA
"Investigating the in vivo roles of lactoferrin in innate immunity and early development using a knockout mouse model"

Stephanie Sibley, MD
Queen’s University, USA
"Prevention of Nosocomial Infections in Critically Ill Patients With Lactoferrin"

Trevor F. Moraes, PhD
University of Toronto, Canada
"Overcoming the antimicrobial properties of Lactoferrin: Roles for the Bacterial Surface Lipoprotein LbpB"

Antonius (Toon) Ligtenberg, PhD
Academic Centre for Dentistry Amsterdam, Nijmegen, Netherlands
"LFchimera and its constituent LFcin and LFampin peptides, an overview"

Jaime Zegarra, MD
Universidad Peruana Cayetano Heredia, Peru

Elsa Chea, MD
Universidad Peruana Cayetano Heredia, Peru

Theresa Ochoa, MD
Universidad Peruana Cayetano Heredia, Peru


Special Symposium on Neonatal Sepsis and Lactoferrin

  • Janet Berrington, MD
    Newcastle University, UK
    ELFIN: the UK preterm lactoferrin trial
  • Nicholas Embleton, PhD
    Newcastle University, UK
    Mechanisms affecting the gut of preterm infants in the ELFIN lactoferrin trial (MAGPIE) using a multi-omic approach
  • David Kaufman, PhD
    University of Virginia, USA
    Optimizing Lactoferrin Dosing in Preterm Infants : Have We Been Studying the Correct Doses?
  • Mohan Pammi, PhD
    Baylor College of Medicine and Texas Children’s Hospital, Houston, USA
    Randomized controlled trial evidence for the use of lactoferrin in neonatal sepsis
  • Stéphane Sizonenko, MD
    Hôpitaux Universitaires de Genève, Switzerland
    Lactoferrin for the developing brain: ready for clinical trial?
  • William Tarnow-Mordi, MD
    University of Sydney, Australia
    Lactoferrin Infant Feeding Trial (LIFT) in very low birth weight infants: a pragmatic RCT
  • Theresa J. Ochoa, MD
    Universidad Peruana Cayetano Heredia, Peru
    The NEOLACTO trials: effect of human lactoferrin intake on sepsis